Please use this identifier to cite or link to this item: https://doi.org/10.1155/2010/435745
Title: Cytokine-induced NK-like T cells: From bench to bedside
Authors: Hui, K.M
Linn, Y.C 
Keywords: carbon tetrachloride
CD27 antigen
CD28 antigen
CD3 antigen
CD56 antigen
chemokine receptor CCR1
chemokine receptor CXCR3
cytokine
gamma interferon
interleukin 12 receptor beta2
interleukin 1beta converting enzyme
interleukin 7 receptor
L selectin
macrophage inflammatory protein 1alpha
RANTES
tumor necrosis factor alpha
acute granulocytic leukemia
acute lymphoblastic leukemia
allograft
animal experiment
antineoplastic activity
cancer cell culture
cancer immunotherapy
chronic lymphatic leukemia
chronic myeloid leukemia
cytokine induced killer cell
cytolysis
cytotoxicity
donor lymphocyte infusion
effector cell
genetic transfection
genotype
graft versus host reaction
graft versus leukemia effect
immunophenotyping
in vitro study
major histocompatibility complex
memory T lymphocyte
mouse
multiple myeloma
nonhuman
ovary carcinoma
phenotype
review
T lymphocyte subpopulation
Th1 cell
tumor cell
adoptive immunotherapy
animal
biotechnology
human
immunology
leukemia
lymphoma
methodology
Animals
Biotechnology
Cytokine-Induced Killer Cells
Humans
Immunotherapy, Adoptive
Leukemia
Lymphoma
Issue Date: 2010
Citation: Hui, K.M, Linn, Y.C (2010). Cytokine-induced NK-like T cells: From bench to bedside. Journal of Biomedicine and Biotechnology 2010 : 435745. ScholarBank@NUS Repository. https://doi.org/10.1155/2010/435745
Rights: Attribution 4.0 International
Abstract: Cytokine-induced killer (CIK) cells are polyclonal T effector cells generated when cultured under cytokine stimulation. CIK cells exhibit potent, non-MHC-restricted cytolytic activities against susceptible tumor cells of both autologous and allogeneic origins. Over the past 20 years, CIK cells have evolved from experimental observations into early clinical studies with encouraging preliminary efficacy towards susceptible autologous and allogeneic tumor cells in both therapeutic and adjuvant settings. This paper is our attempt to summarize the available published literature related to CIK cells. Looking into the future, we anticipate that the continuous therapeutic application of CIK cells will likely be developed along two major directions: overcoming the challenge to organize large prospective randomized clinical trials to define the roles of CIK cells in cancer immunotherapy and expanding its spectrum of cytotoxicity towards resistant tumor cells through experimental manipulations. © 2010 Y. C. Linn and K. M. Hui.
Source Title: Journal of Biomedicine and Biotechnology
URI: https://scholarbank.nus.edu.sg/handle/10635/180990
ISSN: 1110-7243
DOI: 10.1155/2010/435745
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2010_435745.pdf1.25 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

55
checked on Jan 12, 2021

Page view(s)

32
checked on Jan 14, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons